$RKLB

SpaceX vs. Rocket Lab – Which Space Stock Has More Upside, According to Analysts?

SpaceX (SPCX) and Rocket Lab (RKLB) are key players in the space industry. RKLB completed a $1.944B share offering for its Iridium (IRDM) acquisition, aiming to diversify into satellite communications. Analysts see 61.4% upside for RKLB. SPCX targets Starship's first orbital test flight and has a $300 price target, with 49.9% upside. Both companies are expanding into new markets, with analysts highlighting growth opportunities and risks.

Original reporting
Published Sep 18, 2026, 2:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 3:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SpaceX vs. Rocket Lab – Which Space Stock Has More Upside, According to Analysts? — source image
Decision brief

The 30-second read

$RKLBBullishMed
01

Why it matters

New capital raise and acquisition for Rocket Lab, plus a large AI contract and upcoming Starship test for SpaceX, provide fresh catalysts for both stocks.

02

Market read

Both companies are key players in the expanding space sector; recent deals could shift investor allocations.

03

What to watch

Regulatory approvals for the acquisition and AI data privacy concerns may affect outcomes.

Relevance 8/10Novelty 8/10Timing: recently reported

Background

The article compares upside potential of two publicly traded space companies based on recent corporate actions and analyst forecasts.

Company-level read

Ticker impact

$RKLBBullishHigh confidence
Context

Rocket Lab completed a $1.944 billion ATM share offering and announced its planned acquisition of Iridium Communications.

Expected impact

Potential upside if acquisition closes, but short‑term volatility may occur.

Evidence & confidence

Large raise and strategic acquisition provide material growth catalyst.

$SPCXBullishHigh confidence
Context

SpaceX disclosed a new $1.1 billion‑per‑month AI infrastructure deal starting in December and is targeting a Starship orbital test on Sep 28.

Expected impact

Supportive for the stock, especially if the AI contract materializes as expected.

Evidence & confidence

Significant new contract and upcoming test provide fresh growth and risk factors.

Market effects

Both news items highlight accelerating growth in the space and satellite communications sector.

U.S. space‑tech equities may see increased investor interest.

The Iridium acquisition and AI infrastructure deal have worldwide relevance for satellite services.

Counterpoint

Integration risks for Iridium and potential delays in Starship could outweigh upside.

Key entities

  • Rocket Lab USA

    U.S.-listed space launch and satellite services firm (RKLB).

  • SpaceX

    U.S.-listed private space company with public ticker SPCX.

  • Iridium Communications

    Satellite communications provider targeted for acquisition.

Related articles

$SPCXMedAI 8/10

NASA Hitches Ride with SpaceX for StarBurst Satellite. Is RocketLab the Big Loser?

NASA selected SpaceX (SPCX) for a Falcon 9 rideshare mission, including the StarBurst satellite, scheduled for no earlier than 2028. SpaceX reported $3.5B quarterly EBITDA and $93.5B cash, while Rocket Lab (RKLB) remains EBITDA-negative. The deal may impact small-launch providers like Rocket Lab, which has a 137% backlog jump and plans to debut its Neutron rocket in Q4 2026.

$RKLBHighAI 9/10

Rocket Lab Stock Sinks As Dilution Fears Explode

Rocket Lab USA (RKLB) shares fell after completing a $1.94 billion equity offering to fund its Iridium acquisition, increasing outstanding shares. Investors are concerned about dilution, though the company's strong backlog provides some reassurance. Ongoing cash burn and lack of profitability may require further capital.

$SPCXMedAI 8/10

SpaceX at $155: Should You Buy Into Momentum?

SpaceX (SPCX) trades at $155, up 8% in a month, with a $1.89T market cap. Q2 revenue grew 92% to $7.81B, and adjusted EBITDA rose 191% to $3.54B. Analysts' consensus target is $222.42, with bulls citing growth and bears highlighting valuation and execution risks. The stock is above its 50-day and 200-day moving averages but below its 52-week high.